Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
第一作者:
Daniel,Shepshelovich
第一单位:
Daniel Shepshelovich, Hadar Goldvaser, and Eitan Amir, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Daniel Shepshelovich and Hadar Goldvaser, Tel-Aviv University, Tel Aviv, Israel; Ariadna Tibau and Consolación Molto, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona; Alberto Ocana, Castilla La Mancha University, Albacete, Spain; and Bostjan Seruga, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
作者:
主题词
抗肿瘤药(Antineoplastic Agents);药物批准(Drug Approval);药物标签(Drug Labeling);人类(Humans);肿瘤(Neoplasms);产品监测, 售后(Product Surveillance, Postmarketing);随机对照试验(主题)(Randomized Controlled Trials as Topic);美国(United States);美国食品和药物管理局(United States Food and Drug Administration)
DOI
10.1200/JCO.2017.77.5593
PMID
29641296
发布时间
2019-08-12
- 浏览4

Journal of clinical oncology
1798-1804页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文